The Metabolic Effects of Consuming Sugar-Sweetened Beverages for Two Weeks
| Status: | Completed |
|---|---|
| Conditions: | High Cholesterol, Endocrine |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 40 |
| Updated: | 5/5/2014 |
| Start Date: | October 2008 |
| End Date: | February 2014 |
| Contact: | Kimber L Stanhope, Ph.D, R.D. |
| Email: | klstanhope@ucdavis.edu |
| Phone: | (530) 752-6553 |
Effects of 2-weeks Fructose & HFCS Consumption on Dyslipidemia & Insulin Resistance
The purpose of this study is to examine the effects of consumption of sugar-sweetened
beverages on blood triglycerides and cholesterol, cholesterol concentrations, and the body's
sensitivity to insulin.
beverages on blood triglycerides and cholesterol, cholesterol concentrations, and the body's
sensitivity to insulin.
The study is designed as a prospective, blinded diet intervention study during which the
participants consume either fructose- or HFCS-sweetened beverages (providing 10%, 17.5% or
25% of energy) with meals. In addition, there will be two control groups, with one group
consuming 0% sugar beverages sweetened with sucralose and the other consuming
glucose-sweetened beverages at 25% of energy requirement. Experimental procedures, including
24-hour serial blood sampling, post-heparin infusions, gluteal biopsies, Magnetic Resonance
Imaging of the liver and the abdomen, and Oral Glucose Tolerance and Disposal Tests, are
performed during baseline and at the end of a 2-week intervention period at the UC Davis
Clinical and Translational Science Center (CTSC) Clinical Research Center (CCRC). During the
inpatient periods, subjects are served energy balanced diets. The diets provide 15% of
energy as protein, 30% as fat, and 55% as carbohydrate. During baseline testing, the
carbohydrate content consists primarily of complex carbohydrate (>97%). During intervention
the 55% carbohydrate will consist of 10% sugar/45% complex, 17.5% sugar/37.5% complex, or
25% sugar/30% complex depending on the diet group to which the subject is assigned. During
the outpatient intervention periods, the subjects reside at home and are provided with
fructose- or HFCS -sweetened beverages that are consumed with each meal along with a
self-selected ad libitum (usual) diet.
participants consume either fructose- or HFCS-sweetened beverages (providing 10%, 17.5% or
25% of energy) with meals. In addition, there will be two control groups, with one group
consuming 0% sugar beverages sweetened with sucralose and the other consuming
glucose-sweetened beverages at 25% of energy requirement. Experimental procedures, including
24-hour serial blood sampling, post-heparin infusions, gluteal biopsies, Magnetic Resonance
Imaging of the liver and the abdomen, and Oral Glucose Tolerance and Disposal Tests, are
performed during baseline and at the end of a 2-week intervention period at the UC Davis
Clinical and Translational Science Center (CTSC) Clinical Research Center (CCRC). During the
inpatient periods, subjects are served energy balanced diets. The diets provide 15% of
energy as protein, 30% as fat, and 55% as carbohydrate. During baseline testing, the
carbohydrate content consists primarily of complex carbohydrate (>97%). During intervention
the 55% carbohydrate will consist of 10% sugar/45% complex, 17.5% sugar/37.5% complex, or
25% sugar/30% complex depending on the diet group to which the subject is assigned. During
the outpatient intervention periods, the subjects reside at home and are provided with
fructose- or HFCS -sweetened beverages that are consumed with each meal along with a
self-selected ad libitum (usual) diet.
Inclusion Criteria:
- Body mass index between 18-35
- Self report of stable body weight during the past six months
Exclusion Criteria:
- Diabetes Mellitus
- Evidence of liver disorder
- Evidence of kidney disorder
- Evidence of thyroid disorder
- Systolic blood pressure consistently over 160mmHg or diastolic blood pressure over
900mmHg
- Triglycerides > 400mg/dl
- LDL-C > 240mg/dl
- Hemoglobin < 8.5 g/dl
- Current, prior (within 2 months), or anticipated use of any hypolipidemic or
anti-diabetic agents
- Use of Selective Serotonin Reuptake Inhibitors and anti-hypertensive medications
- Any other condition that, in the opinion of the investigators, would put subject at
risk
- Strenuous exerciser
- Pregnant or lactating women
- Smoker
- Diet exclusions: food allergies, special dietary restrictions, habitual ingest of >2
alcoholic beverages/day
We found this trial at
1
site
Click here to add this to my saved trials
